The disease relevance of human hepatocellular xenograft models: molecular characterization and review of the literature.
暂无分享,去创建一个
F Iberer | K Zatloukal | K. Zatloukal | H. Mischinger | F. Iberer | M. M. Tschernatsch | K Kashofer | M M Tschernatsch | H J Mischinger | K. Kashofer
[1] David S. Taylor,et al. Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[2] N. Tamaoki,et al. In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. , 1981, Journal of immunology.
[3] Alona Muzikansky,et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] B. Giovanella,et al. Development of invasive tumors in the "nude" mouse after injection of cultured human melanoma cells. , 1972, Journal of the National Cancer Institute.
[5] Ivan Damjanov,et al. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line , 1979, Nature.
[6] Kiyoko F. Aoki-Kinoshita,et al. From genomics to chemical genomics: new developments in KEGG , 2005, Nucleic Acids Res..
[7] P. Schein,et al. Barriers to Efficient Development of Cancer Therapeutics , 2006, Clinical Cancer Research.
[8] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[9] H. Wortis,et al. ABNORMAL DEVELOPMENT OF THE THYMUS IN "NUDE" MICE , 1971, The Journal of experimental medicine.
[10] S. Thorgeirsson,et al. Molecular pathogenesis of human hepatocellular carcinoma , 2002, Nature Genetics.
[11] D. Greiner,et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. , 1995, Journal of immunology.
[12] Jeffrey W. Clark,et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma , 2007, Cancer.
[13] F. Alt,et al. Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation , 1995, Cell.
[14] R. Custer,et al. A severe combined immunodeficiency mutation in the mouse , 1983, Nature.
[15] D. Schmähl,et al. Zur Morphologie der durch Diäthylnitrosamin erzeugten Lebertumoren bei der Maus und dem Meerschweinchen , 1963, Zeitschrift für Krebsforschung.
[16] Yoshihiro Yamanishi,et al. KEGG for linking genomes to life and the environment , 2007, Nucleic Acids Res..
[17] Guan-Tarn Huang,et al. Hepatocyte Growth Factor Stimulates the Growth and Activates Mitogen-Activated Protein Kinase in Human Hepatoma Cells , 1998, Journal of Biomedical Sciences.
[18] Derek Y. Chiang,et al. Genomics and signaling pathways in hepatocellular carcinoma. , 2007, Seminars in liver disease.
[19] Susumu Goto,et al. KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..
[20] M R Grever,et al. In vivo cultivation of tumor cells in hollow fibers. , 1995, Life sciences.
[21] K. Kaestner,et al. Unified nomenclature for the winged helix/forkhead transcription factors. , 2000, Genes & development.
[22] B. Carr,et al. Concomitant and isolated expression of TGF‐alpha and EGF‐R in human hepatoma cells supports the hypothesis of autocrine, paracrine, and endocrine growth of human hepatoma , 1995, Journal of surgical oncology.
[23] I. Fidler,et al. Environmental and genetic factors determine the level of NK activity of nude mice and affect their suitability as models for experimental metastasis , 1982, International journal of cancer.
[24] K. Chai,et al. In vitro anti-proliferative effect of 1,2,3,4,6-penta-O-galloyl-beta-D-glucose on human hepatocellular carcinoma cell line, SK-HEP-1 cells. , 2001, Cancer letters.
[25] S. Kuo,et al. CHM-1 inhibits hepatocyte growth factor-induced invasion of SK-Hep-1 human hepatocellular carcinoma cells by suppressing matrix metalloproteinase-9 expression. , 2007, Cancer letters.
[26] S. Heffelfinger,et al. SK HEP-1: A human cell line of endothelial origin , 1992, In Vitro Cellular & Developmental Biology - Animal.
[27] D. Amadori,et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Cristel G. Thomas,et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry , 2007, Hepatology.
[29] M. Christian,et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials , 2001, British Journal of Cancer.
[30] T. Orfeo,et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. , 1977, Journal of the National Cancer Institute.
[31] Li Zhao,et al. Expression of cancer-testis antigens in hepatocellular carcinoma. , 2004, World journal of gastroenterology.
[32] J. Rygaard,et al. Heterotransplantation of a human malignant tumour to "Nude" mice. , 2009, Acta pathologica et microbiologica Scandinavica.
[33] H. Hirte,et al. BAY 43-9006: early clinical data in patients with advanced solid malignancies. , 2002, Current pharmaceutical design.
[34] J. Venditti,et al. Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions. , 1984, Advances in pharmacology and chemotherapy.
[35] M. Kojiro,et al. Expression of vascular endothelial growth factor in human hepatocellular carcinoma , 1998, Hepatology.
[36] Y. Watanabe,et al. Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. , 2008, Liver.
[37] Thomas Boehm,et al. New member of the winged-helix protein family disrupted in mouse and rat nude mutations , 1994, Nature.
[38] S. Flanagan,et al. 'Nude', a new hairless gene with pleiotropic effects in the mouse. , 1966, Genetical research.
[39] S. Thorgeirsson,et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer , 2004, Nature Genetics.
[40] Jeffrey S. Morris,et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma , 2007, Cancer.
[41] J. Sheu. Molecular mechanism of hepatocarcinogenesis , 1997, Journal of gastroenterology and hepatology.
[42] A. Groen,et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. , 1994, The American journal of pathology.
[43] M. Bibby,et al. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[44] Rolf Gebhardt,et al. Correlation between β-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma , 2008, Molecular Cancer.
[45] H. Kawasaki,et al. Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. , 1999, Liver.
[46] G. Giannelli,et al. Novel Concepts in Hepatocellular Carcinoma: From Molecular Research to Clinical Practice , 2006, Journal of clinical gastroenterology.